Name Sandro Porceddu | ||
 | ||
2018 Skin Cancer Summit - Professor Sandro Porceddu
Sandro Porceddu is a head and neck radiation oncologist at Brisbane's Princess Alexandra Hospital and a Professor with the University of Queensland. He was president of the Clinical Oncologic Society of Australia (COSA) and chair of the Trials Scientific Committee of the Trans Tasman Radiation Oncology Group (TROG).
Contents
- 2018 Skin Cancer Summit Professor Sandro Porceddu
- Tackling the rare cancers what can be done by dr sandro porceddu
- Academic career
- Publications
- References
Tackling the rare cancers what can be done by dr sandro porceddu
Academic career
Porceddu was awarded a doctorate of medicine for his research into improving the integration of radiotherapy in the management of head and neck cancer and received the American Head and Neck Society/ANZ Head and Neck Cancer Society Christopher O’Brien Traveling Scholarship. He is chair of a phase 3 clinical trial group to assess radiation therapy alone versus in combination with carboplatin chemotherapy for the post-operative treatment of head and neck cancers.
Publications
1. Sandro V Porceddu (2013). "Does fluorodeoxyglucose PET add to the management of the neck following curative radiotherapy in head and neck cancer compared with computed tomography?". Expert Rev Anticancer Ther. 13: 279–84. doi:10.1586/era.13.10.
2. Sandro V Porceddu (2005). "Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer". Head Neck. 27: 175–81. PMID 15627258. doi:10.1002/hed.20130.
3. Sandro V Porceddu (2007). "Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment--"Hypo Trial"". Radiother Oncol. 85: 456–62. PMID 18036689. doi:10.1016/j.radonc.2007.10.020.
4. Sandro V Porceddu (2008). "Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond". Hematol Oncol Clin North Am. 22: 1221–38, ix–x. doi:10.1016/j.hoc.2008.08.009.
5. S V Porceddu (2008). "Predicting regional control based on pretreatment nodal size in squamous cell carcinoma of the head and neck treated with chemoradiotherapy: a clinician's guide". J Med Imaging Radiat Oncol. 52: 491–6. doi:10.1111/j.1440-1673.2008.02001.x.
6. Sandro V Porceddu (2011). "Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy". Head Neck. 33: 1675–82. doi:10.1002/hed.21655.
7. J Corry (2008). "Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation". J Med Imaging Radiat Oncol. 52: 503–510. doi:10.1111/j.1440-1673.2008.02003.x.
8. D I Pryor (2011). "Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma". Oral Oncol. 1747: 984–7. doi:10.1016/j.oraloncology.2011.07.023.
9. M K Ng (2005). "Parotid-sparing radiotherapy: does it really reduce xerostomia?". Clin Oncol (R Coll Radiol). 17: 610–7. PMID 16372486.
10. Sandro V. Porceddu, Belinda Campbell, Danny Rischin, June Corry, LeAnn Weih, Mario Guerrieri, Marissa Grossi, Lester J. Peters (October 1, 2004). "Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma". International Journal of Radiation Oncology*Biology*Physics. 60 (2): 365–373. doi:10.1016/j.ijrobp.2004.03.011. CS1 maint: Uses authors parameter (link)
11. David I Pryor, Benjamin Solomon, Sandro V Porceddu (September 2011). "The emerging era of personalized therapy in squamous cell carcinoma of the head and neck". Asia-Pacific Journal of Clinical Oncology. 7 (3): 236–251. doi:10.1111/j.1743-7563.2011.01420.x. CS1 maint: Uses authors parameter (link)